{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/VCRE",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Vicore Pharma Holding AB (NASDAQ: VCRE) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Vicore Pharma Holding AB, listed on NASDAQ under ticker VCRE, with ISIN US92581R1041. The LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-V7. The security type is non-operating entity type (other), sector 2834 Pharmaceutical Preparations, jurisdiction Sweden, and segment not on the record. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 13 filings in the window 2025-11-08 to 2026-11-08, across 11 filing days, of which 7 are regulatory filings and 6 are results. The median gap between filing days is 15.5 days. The latest filing is dated 2026-11-05, a results filing, 3 days before the record date of 2026-11-08. On NASDAQ the median cadence gap is 6.0 days, the median filings count is 52, and the median latency is 5.0 days across 4359 issuers. In sector 2834 Pharmaceutical Preparations the median cadence gap is 6.0 days, the median filings count is 63.0, and the median latency is 4.0 days across 526 issuers.\n\n## Auditor\n\nThe auditor of record is not on the record, as the latest annual report cover carries no dei:AuditorName tag, and the auditor's location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds one lifecycle line, a listing dated 2026-06-30. It holds no delisting, name change, or domicile change, and the segment move is not on the record. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe orderability outcome is not determinable, as the chapter's orderability section carries no client categories and the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe record finds 11 research houses named on the issuer's investor-relations page: ABG Sundal Collier, Cantor, Danske Bank, DNB Carnegie, Guggenheim, Jefferies, Pareto Securities, Stifel, Van Lanschot Kempen, Arctic Securities, and Chardan.\n\n## Open research\n\nThe record holds one openly published research note, by Goetzpartners Healthcare Research, dated 2018-03-22.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe sealed years that hold the issuer are 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0002124403.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/VCRE (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://vicorepharma.com/investerare/aktieinformation-2/analytiker/ (coverage)\n- http://vicorepharma.com/wp-content/uploads/2019/06/goetz-partners-vph-180322.pdf (open research)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/VCRE (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/VCRE",
  "coverage": {
   "count": 11,
   "houses": [
    {
     "analyst": "Georg Tigalonov-Bjerke",
     "house": "ABG Sundal Collier",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Steve Seedhouse",
     "house": "Cantor",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Gonzalo Artiach",
     "house": "Danske Bank",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Arvid Necander",
     "house": "DNB Carnegie",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Vamil Divan",
     "house": "Guggenheim",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Faisal Khurshid",
     "house": "Jefferies",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Chien-Hsun Lee",
     "house": "Pareto Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Clemence Thiers",
     "house": "Stifel",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Sushila Hernandez",
     "house": "Van Lanschot Kempen",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Gasper Virant",
     "house": "Arctic Securities",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    },
    {
     "analyst": "Andreas Argyrides",
     "house": "Chardan",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/",
     "result": "read: 11 of 20 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "regulatory_filing": 7,
    "results": 6
   },
   "cadence_median_gap_days": 15.5,
   "filing_days": 11,
   "filings": 13,
   "latency_days": 3,
   "latest": [
    {
     "category": "6-K",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/2124403/000143774926035333/vcre20260825_6k.htm",
     "title": "6-K — FORM 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-11-03",
     "source": "https://www.sec.gov/Archives/edgar/data/2124403/000143774926034704/vcre20261103_6k.htm",
     "title": "6-K — FORM 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-10-22",
     "source": "https://www.sec.gov/Archives/edgar/data/2124403/000143774926033290/vcre20261022c_6k.htm",
     "title": "6-K — FORM 6-K",
     "type": "results"
    },
    {
     "category": "SCHEDULE 13G",
     "date": "2026-10-13",
     "source": "https://www.sec.gov/Archives/edgar/data/2124403/000110465926115489/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G",
     "type": "regulatory_filing"
    },
    {
     "category": "6-K",
     "date": "2026-09-30",
     "source": "https://www.sec.gov/Archives/edgar/data/2124403/000143774926031613/vcre20260929_6k.htm",
     "title": "6-K — FORM 6-K",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/VCRE",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-14",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US92581R1041"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002124403.json",
    "state": "sourced",
    "value": "Sweden"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-V7",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002124403.json",
    "state": "sourced",
    "value": "Vicore Pharma Holding AB"
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002124403.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002124403.json",
    "state": "sourced",
    "value": "Non-operating entity type (other)"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "VCRE"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [
    {
     "date": "2026-06-30",
     "source": "https://www.sec.gov/Archives/edgar/data/2124403/000135445726000627/2124403_20F_Cert_VCRE.pdf",
     "title": "CERT"
    }
   ],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:ee4f12127b721ee606d212afb32a6ee29722634851fdc98717e6afdf8aa93c83",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [
    {
     "date": "2018-03-22",
     "kind": "issuer-sponsored",
     "publisher": "Goetzpartners Healthcare Research",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "http://vicorepharma.com/wp-content/uploads/2019/06/goetz-partners-vph-180322.pdf",
     "state": "sourced",
     "title": "Novel approach to tackle fibrotic orphan diseases"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/VCRE",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:ee4f12127b721ee606d212afb32a6ee29722634851fdc98717e6afdf8aa93c83",
 "path": "/us/NASDAQ/VCRE",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Vicore Pharma Holding AB, listed on NASDAQ under ticker VCRE, with ISIN US92581R1041. The LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-V7. The security type is non-operating entity type (other), sector 2834 Pharmaceutical Preparations, jurisdiction Sweden, and segment not on the record. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 13 filings in the window 2025-11-08 to 2026-11-08, across 11 filing days, of which 7 are regulatory filings and 6 are results. The median gap between filing days is 15.5 days. The latest filing is dated 2026-11-05, a results filing, 3 days before the record date of 2026-11-08. On NASDAQ the median cadence gap is 6.0 days, the median filings count is 52, and the median latency is 5.0 days across 4359 issuers. In sector 2834 Pharmaceutical Preparations the median cadence gap is 6.0 days, the median filings count is 63.0, and the median latency is 4.0 days across 526 issuers.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record, as the latest annual report cover carries no dei:AuditorName tag, and the auditor's location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds one lifecycle line, a listing dated 2026-06-30. It holds no delisting, name change, or domicile change, and the segment move is not on the record. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The orderability outcome is not determinable, as the chapter's orderability section carries no client categories and the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The record finds 11 research houses named on the issuer's investor-relations page: ABG Sundal Collier, Cantor, Danske Bank, DNB Carnegie, Guggenheim, Jefferies, Pareto Securities, Stifel, Van Lanschot Kempen, Arctic Securities, and Chardan.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "The record holds one openly published research note, by Goetzpartners Healthcare Research, dated 2018-03-22.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The sealed years that hold the issuer are 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0002124403.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/VCRE"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://vicorepharma.com/investerare/aktieinformation-2/analytiker/"
  },
  {
   "for": "open research",
   "source": "http://vicorepharma.com/wp-content/uploads/2019/06/goetz-partners-vph-180322.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/VCRE"
  }
 ],
 "title": "Vicore Pharma Holding AB (VCRE) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}